Ajit S. Narang works for the Bristol-Myers Squibb, Co. in New Brunswick, New Jersey, in the biopharmaceutical aspects of drug delivery. He has more than eight years of experience in the pharmaceutical industry in the development of oral dosage forms and drug delivery platforms. In addition to the Bristol-Myers Squibb, Co., he has worked for Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) in Gurgaon, India, and Morton Grove Pharmaceuticals (currently a subsidiary of Wockhardt USA LLC, Parsippany, New Jersey) in Vernon Hills, Illinois. He has more than 35 publications and three pending patent applications, and has contributed to the development of several marketed drug products. Ram I. Mahato is a full-time professor in the Department of Pharmaceutical Sciences at the University of Health Science Center, Memphis, Tennessee. He was a research assistant professor at the University of Utah, Salt Lake City; a senior scientist at GeneMedicine, Inc., The Woodland, Texas; and a postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University, Japan. He is an author or coauthor of 79 peer-reviewed articles and book chapters, and has edited/written three books. He is also a special features editor of Pharmaceutical Research and serves on the editorial boards of the Journal of Drug Targeting, Expert Opinion on Drug Delivery, and Transplantation and Risk Management. His research includes delivery and targeting of small molecules, oligonucleotides, siRNA, and genes.

• ACTIVE TARGETING. NUCLEIC ACID DELIVERY AND TARGETING. INTRACELLULAR/ORGANELLE-PART SPECIFIC STRATEGIES. PRODRUG STRATEGIES. ORGAN- OR TISSUE-SPECIFIC DRUG DELIVERY. POLYMER–DRUG CONJUGATES AND MICELLES. STIMULI-RESPONSIVE SYSTEMS.

Select Guide Rating

Ajit S. Narang works for the Bristol-Myers Squibb, Co. in New Brunswick, New Jersey, in the biopharmaceutical aspects of drug delivery. He has more than eight years of experience in the pharmaceutical industry in the development of oral dosage forms and drug delivery platforms. In addition to the Bristol-Myers Squibb, Co., he has worked for Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) in Gurgaon, India, and Morton Grove Pharmaceuticals (currently a subsidiary of Wockhardt USA LLC, Parsippany, New Jersey) in Vernon Hills, Illinois. He has more than 35 publications and three pending patent applications, and has contributed to the development of several marketed drug products. Ram I. Mahato is a full-time professor in the Department of Pharmaceutical Sciences at the University of Health Science Center, Memphis, Tennessee. He was a research assistant professor at the University of Utah, Salt Lake City; a senior scientist at GeneMedicine, Inc., The Woodland, Texas; and a postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University, Japan. He is an author or coauthor of 79 peer-reviewed articles and book chapters, and has edited/written three books. He is also a special features editor of Pharmaceutical Research and serves on the editorial boards of the Journal of Drug Targeting, Expert Opinion on Drug Delivery, and Transplantation and Risk Management. His research includes delivery and targeting of small molecules, oligonucleotides, siRNA, and genes.

• ACTIVE TARGETING. NUCLEIC ACID DELIVERY AND TARGETING. INTRACELLULAR/ORGANELLE-PART SPECIFIC STRATEGIES. PRODRUG STRATEGIES. ORGAN- OR TISSUE-SPECIFIC DRUG DELIVERY. POLYMER–DRUG CONJUGATES AND MICELLES. STIMULI-RESPONSIVE SYSTEMS.

Select Guide Rating

Ajit S. Narang works for the Bristol-Myers Squibb, Co. in New Brunswick, New Jersey, in the biopharmaceutical aspects of drug delivery. He has more than eight years of experience in the pharmaceutical industry in the development of oral dosage forms and drug delivery platforms. In addition to the Bristol-Myers Squibb, Co., he has worked for Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) in Gurgaon, India, and Morton Grove Pharmaceuticals (currently a subsidiary of Wockhardt USA LLC, Parsippany, New Jersey) in Vernon Hills, Illinois. He has more than 35 publications and three pending patent applications, and has contributed to the development of several marketed drug products. Ram I. Mahato is a full-time professor in the Department of Pharmaceutical Sciences at the University of Health Science Center, Memphis, Tennessee. He was a research assistant professor at the University of Utah, Salt Lake City; a senior scientist at GeneMedicine, Inc., The Woodland, Texas; and a postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University, Japan. He is an author or coauthor of 79 peer-reviewed articles and book chapters, and has edited/written three books. He is also a special features editor of Pharmaceutical Research and serves on the editorial boards of the Journal of Drug Targeting, Expert Opinion on Drug Delivery, and Transplantation and Risk Management. His research includes delivery and targeting of small molecules, oligonucleotides, siRNA, and genes.

• ACTIVE TARGETING. NUCLEIC ACID DELIVERY AND TARGETING. INTRACELLULAR/ORGANELLE-PART SPECIFIC STRATEGIES. PRODRUG STRATEGIES. ORGAN- OR TISSUE-SPECIFIC DRUG DELIVERY. POLYMER–DRUG CONJUGATES AND MICELLES. STIMULI-RESPONSIVE SYSTEMS.

Select Guide Rating